Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
作者： D C Betticher , , S-F Hsu Schmitz , M Tötsch , E Hansen
关键词: Surgery 、 Medicine 、 Respiratory disease 、 Phases of clinical research 、 Lung 、 Internal medicine 、 Docetaxel 、 Cisplatin 、 Lung cancer 、 Mediastinoscopy 、 Gastroenterology 、 Chemotherapy
摘要: The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled) underwent tumour resection after three 3-week cycles docetaxel 85 mg m-2 (day 1) plus cisplatin 40 or 50 (days 1 2). Therapy well tolerated (overall grade 3 toxicity occurred 48% patients; no 4 nonhaematological reported), with observed late toxicities. Median overall survival (OS) event-free (EFS) times were 35 15 months, respectively, who surgery; corresponding figures all enrolled 28 12 months. At years initiating trial therapy, 27 out (36%) alive free. 5-year follow-up, 60 65% had local relapse distant metastases, respectively. most common sites metastases (24%) brain (17%). Factors associated OS, EFS risk complete chemotherapy activity (clinical response, pathologic mediastinal downstaging). Neoadjuvant effective tolerable pN2 NSCLC, contributing significantly outcomes.
nature.com
core.ac.uk
sci-hub.se 参考文章(33)
G. M. Strauss, J. Herndon, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. M. Watson, D. J. Sugarbaker, R. L. Schilsky, M. R. Green, Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 Journal of Clinical Oncology. ,vol. 22, pp. 7019- 7019 ,(2004) , 10.1200/JCO.2004.22.14_SUPPL.7019
K. S. Albain, R. S. Swann, V. R. Rusch, A. T. Turrisi, F. A. Shepherd, C. J. Smith, D. R. Gandara, D. H. Johnson, M. R. Green, R. C. Miller, Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) Journal of Clinical Oncology. ,vol. 23, pp. 7014- 7014 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.7014
K S Albain, V W Rusch, J J Crowley, T W Rice, A T Turrisi, J K Weick, V A Lonchyna, C A Presant, R J McKenna, D R Gandara, Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. Journal of Clinical Oncology. ,vol. 13, pp. 1880- 1892 ,(1995) , 10.1200/JCO.1995.13.8.1880
N C Choi, R W Carey, W Daly, D Mathisen, J Wain, C Wright, T Lynch, M Grossbard, H Grillo, Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer Journal of Clinical Oncology. ,vol. 15, pp. 712- 722 ,(1997) , 10.1200/JCO.1997.15.2.712
W Eberhardt, H Wilke, G Stamatis, M Stuschke, A Harstrick, H Menker, B Krause, M R Müeller, M Stahl, M Flasshove, V Budach, D Greschuchna, N Konietzko, H Sack, S Seeber, Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. Journal of Clinical Oncology. ,vol. 16, pp. 622- 634 ,(1998) , 10.1200/JCO.1998.16.2.622
R L Burkes, R J Ginsberg, F A Shepherd, M E Blackstein, M E Goldberg, P F Waters, G A Patterson, T Todd, F G Pearson, J D Cooper, Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. Journal of Clinical Oncology. ,vol. 10, pp. 580- 586 ,(1992) , 10.1200/JCO.1992.10.4.580
F. Andre, D. Grunenwald, J. L. Pujol, P. Girard, A. Dujon, L. Brouchet, P. Y. Brichon, V. Westeel, T. Le Chevalier, Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer. ,vol. 91, pp. 2394- 2400 ,(2001) , 10.1002/1097-0142(20010615)91:12<2394::AID-CNCR1273>3.0.CO;2-6
A.D. Elias, A.T. Skarin, T. Leong, S. Mentzer, G. Strauss, T. Lynch, L. Shulman, C. Jacobs, A. Abner, E.H. Baldini, E. Frei, D.J. Sugarbaker, Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC) Lung Cancer. ,vol. 17, pp. 147- 161 ,(1997) , 10.1016/S0169-5002(97)00658-2
Raphael Bueno, William G Richards, Scott J Swanson, Michael T Jaklitsch, Jeanne M Lukanich, Steven J Mentzer, David J Sugarbaker, Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. The Annals of Thoracic Surgery. ,vol. 70, pp. 1826- 1831 ,(2000) , 10.1016/S0003-4975(00)01585-X
Samir Darwish, Vincenzo Minotti, Lucio Crinó, Riccardo Rossetti, Paolo Fiaschini, Ernesto Maranzano, Franco Checcaglini, Tommaso Todisco, Michele Giansanti, Ugo Mercati, Rino Vitali, Paolo Latini, Maurizio Tonat, A phase ii trial of combined chemotherapy and surgery in stage iiia non-small cell lung cancer Lung Cancer. ,vol. 12, ,(1995) , 10.1016/0169-5002(95)00422-W